SCHEMBL6441202

SCHEMBL6441202

N#Cc1c(N)nc(N)nc1-c1ccco1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 11/20 0.72
ADORA1 P30542 10/20 0.72
ADORA2B P29275 8/20 0.72
DHFR P00374 1/20 0.54
ALDH1A1 P00352 7/20 0.53
MEN1 O00255 5/20 0.53
KMT2A Q03164 5/20 0.53
HSD17B10 Q99714 5/20 0.53
HPGD P15428 4/20 0.53
CASP1 P29466 2/20 0.53
BLM P54132 1/20 0.53
KDM4E B2RXH2 6/20 0.51
GAA P10253 3/20 0.51
POLB P06746 2/20 0.51
MAPT P10636 3/20 0.50
GLA P06280 2/20 0.50
TSHR P16473 2/20 0.50
ADORA3 P0DMS8 1/20 0.50
PSMD14 O00487 1/20 0.50
USP2 O75604 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5041600 0.86 ADORA2A (0.70) ADORA2AADORA1ADORA2BDHFRALDH1A1
SCHEMBL11838487 0.85 ALDH1A1 (0.57) ADORA2AADORA1ADORA2BALDH1A1MEN1
SCHEMBL6440893 0.85 ADORA2A (0.68) ADORA2AADORA1ADORA2BALDH1A1MEN1
SCHEMBL5039804 0.84 ADORA1 (1.00) ADORA2AADORA1ADORA2BALDH1A1MEN1
SCHEMBL6446123 0.82 ADORA2A (0.65) ADORA2AADORA1ADORA2BALDH1A1MEN1
SCHEMBL6442193 0.81 ADORA2A (0.64) ADORA2AADORA1ADORA2BALDH1A1MEN1
SCHEMBL6443406 0.81 ADORA2A (0.64) ADORA2AADORA1ADORA2BALDH1A1MEN1
SCHEMBL6441106 0.81 ADORA2A (0.64) ADORA2AADORA1ADORA2BALDH1A1MEN1
SCHEMBL6441851 0.81 ADORA2A (0.64) ADORA2AADORA1ADORA2BALDH1A1MEN1
Benzene SCHEMBL6444041 0.81 ADORA2A (0.67) ADORA2AADORA1ADORA2BALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1261327-B1 ADENOSINE RECEPTOR MODULATORS HOFFMANN LA ROCHE (CH) 2005-04-27 EP disclosed
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 ADORA2A 1/4885ADORA1 3/4885ADORA2B 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.